Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precis...
Published online May 16 in the journal Cell, the report describes the molecular mechanism behind a DNA repair pathway that counters the mistaken inclusion ...
Research in MPS IVA led by REGENXBIO scientists moving into clinic Donation of NAV® Technology licenses will support development...
Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access...
SomaLogic, Inc., a global leader in proteomics technology, announced that it is sponsoring the Genomax Research Grant Award for researchers in Singapore. T...
Largely driven by increasing incidence of chronic and infectious diseases and growth in biotechnology and pharma industries, the global immunoassay market ...
Nicola Thompson, CEO of Amphista, said, "We are absolutely delighted with the progress and success of our collaboration with BMS. Our ability to deliver ou...
The proposed non-clinical studies will investigate pharmacodynamic biomarkers for ST316, a first-in-class β-catenin antagonist, and evaluate the impac...
© 2023 Biopharma Boardroom. All Rights Reserved.
